Evidence map›Paper›PMID 41918864›Full record

ArticlePeerJ2026

Indobufen

Sijie Jiang, Lilong Lin, Xiaolin Duan, Jianqin Zhang, Yuqing Hou, Lan Gong, Qingchun Zeng, Hua Zheng

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sijie Jiang *Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Lilong Lin *Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiaolin DuanDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jianqin ZhangDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yuqing HouDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Lan GongUNSW Microbiome Research Centre, St George and Sutherland Clinical Campus, University of New South Wales, Sydney, Australia.
Qingchun ZengDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hua ZhengDepartment of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This retrospective study compared the effects of indobufen versus aspirin, each combined with clopidogrel, on serum uric acid (SUA) levels and gout attacks in patients undergoing coronary stenting. Methods: Among 213 enrolled patients, 156 were included after propensity score matching and assigned to either the indobufen plus clopidogrel group ( Results: Baseline characteristics were comparable. The indobufen group showed significant reductions in SUA levels at all follow-ups (all, Conclusion: Indobufen plus clopidogrel significantly reduced SUA levels and showed a favorable trend in reducing gout recurrences without compromising cardiovascular safety.

Indexed as

AspirinGoutPlatelet Aggregation InhibitorsUric AcidAgedClopidogrelDrug Therapy, CombinationDual Anti-Platelet TherapyFemaleHumansMaleMiddle AgedRetrospective StudiesStentsTreatment OutcomeAspirinClopidogrelPlatelet Aggregation InhibitorsUric AcidDual antiplatelet therapyGoutIndobufenSerum uric acid

Identifiers

PMID41918864
PMCPMC13034863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.